Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pacritinib citrate

(pak-RIH-tih-nib SIH-trayt)
A drug used to treat adults with intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. It is used in patients who have a very low blood platelet count. It is also being studied in the treatment of other conditions and some types of cancer. Pacritinib citrate blocks JAK2 and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of kinase inhibitor. Also called Vonjo.
Search NCI's Dictionary of Cancer Terms